UB Paderborn / Katalog / Suche / in CDI

Novel myostatin-specific antibody enhances muscle strength in muscle disease models

Scientific reports, 2021-01, Vol.11 (1), p.2160-16, Article 2160

2021

Volltextzugriff (PDF)

An Inhibitor of p38 Mitogen-activated Protein Kinase Prevents Insulin-stimulated Glucose Transport but Not Glucose Transporter Translocation in 3T3-L1 Adipocytes and L6 Myotubes

The Journal of biological chemistry, 1999-04, Vol.274 (15), p.10071-10078

1999

Volltextzugriff (PDF)

Insulin-induced cortical actin remodeling promotes GLUT4 insertion at muscle cell membrane ruffles

The Journal of clinical investigation, 2001-08, Vol.108 (3), p.371-381

2001

Volltextzugriff (PDF)

Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance

Journal of Diabetes Research, 2016-01, Vol.2016, p.8264830-13

2016

Volltextzugriff (PDF)

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro

TH open : companion journal to thrombosis and haemostasis, 2018-01, Vol.2 (1), p.e96-e103

2018

Volltextzugriff (PDF)

GLUT-4myc ectopic expression in L6 myoblasts generates a GLUT-4-specific pool conferring insulin sensitivity

American journal of physiology: endocrinology and metabolism, 1999-09, Vol.277 (3), p.E572-E578

1999

Volltextzugriff (PDF)

Rapid stimulation of glucose transport by mitochondrial uncoupling depends in part on cytosolic Ca2+ and cPKC

American Journal of Physiology: Cell Physiology, 1998-12, Vol.275 (6), p.C1487

1998

Volltextzugriff (PDF)

Nonradioisotope assay of glucose uptake activity in rat skeletal muscle using enzymatic measurement of 2-deoxyglucose 6-phosphate in vitro and in vivo

Biological signals and receptors, 2000-09, Vol.9 (5), p.267

2000

Volltextzugriff (PDF)

Identification of GFAT1-L, a novel splice variant of human glutamine: fructose-6-phosphate amidotransferase (GFAT1) that is expressed abundantly in skeletal muscle

Journal of human genetics, 2001-01, Vol.46 (10), p.566-571

2001

Volltextzugriff (PDF)

Rapid stimulation of glucose transport by mitochondrial uncoupling depends in part on cytosolic Ca 2+ and cPKC

American Journal of Physiology: Cell Physiology, 1998-12, Vol.275 (6), p.C1487-C1497

1998

Volltextzugriff (PDF)

GLUT-4myc ectopic expression in L6 myoblasts generates a GLUT-4-specific pool conferring insulin sensitivity

American journal of physiology: endocrinology and metabolism, 1999-09, Vol.40 (3), p.E572-E578

1999

Volltextzugriff (PDF)

Rapid stimulation of glucose transport by mitochondrial uncoupling depends in part on cytosolic Ca2+ and cPKC

American Journal of Physiology: Cell Physiology, 1998-12, Vol.44 (6), p.1487-1497

1998

Volltextzugriff (PDF)

GLUT-4myc ectopic expression in L6 myoblasts generates a GLUT-4-specific pool conferring insulin sensitivity

American journal of physiology: endocrinology and metabolism, 1999-09, Vol.277 (3), p.E572

1999

Volltextzugriff (PDF)

Heterogeneity of fractionated alveolar macrophages in starved rats

Nutrition research (New York, N.Y.), 1990-10, Vol.10 (10), p.1141-1149

1990

Volltextzugriff (PDF)

Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials

Endocrine Journal, 2018, Vol.65(7), pp.693-705

2018

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus

British journal of clinical pharmacology, 2019-08, Vol.85 (8), p.1808-1819

2019

Volltextzugriff (PDF)

Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study

Diabetology international, 2015-06, Vol.6 (2), p.125-138

2015

Volltextzugriff (PDF)

Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)

Diabetology international, 2015-06, Vol.6 (2), p.104-116

2015

Volltextzugriff (PDF)

Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus

Diabetes therapy, 2020-04, Vol.11 (4), p.951-964

2020

Volltextzugriff (PDF)

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials

Journal of diabetes investigation, 2016-07, Vol.7 (4), p.544-554

2016

Volltextzugriff (PDF)

Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin : a pooled analysis of six randomized, placebo-controlled trials

ENDOCRINE JOURNAL, 2018, Vol.65 (7), p.693-705

2018

Volltextzugriff (PDF)

Effects of ipragliflozin, a selective sodium–glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials

Diabetology international, 2017-03, Vol.8 (1), p.76-86

2017

Volltextzugriff (PDF)

Effects of Ipragliflozin, a Selective Sodium–Glucose Co-Transporter 2 Inhibitor, on Blood Pressure in Japanese Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Six Randomized, Placebo-Controlled Clinical Trials

Journal of hypertension, 2015-06, Vol.33 (Supplement 2), p.e2

2015

Volltextzugriff (PDF)

Loss of 3p26.3 is an independent prognostic factor in patients with oral squamous cell carcinoma

Oncology reports, 2011-08, Vol.26 (2), p.463-469

2011

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Novel myostatin-specific antibody enhances muscle strength in muscle disease models

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

An Inhibitor of p38 Mitogen-activated Protein Kinase Prevents Insulin-stimulated Glucose Transport but Not Glucose Transporter Translocation in 3T3-L1 Adipocytes and L6 Myotubes

Insulin-induced cortical actin remodeling promotes GLUT4 insertion at muscle cell membrane ruffles

Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro

GLUT-4myc ectopic expression in L6 myoblasts generates a GLUT-4-specific pool conferring insulin sensitivity

Rapid stimulation of glucose transport by mitochondrial uncoupling depends in part on cytosolic Ca2+ and cPKC

Nonradioisotope assay of glucose uptake activity in rat skeletal muscle using enzymatic measurement of 2-deoxyglucose 6-phosphate in vitro and in vivo

Identification of GFAT1-L, a novel splice variant of human glutamine: fructose-6-phosphate amidotransferase (GFAT1) that is expressed abundantly in skeletal muscle

Rapid stimulation of glucose transport by mitochondrial uncoupling depends in part on cytosolic Ca 2+ and cPKC

GLUT-4myc ectopic expression in L6 myoblasts generates a GLUT-4-specific pool conferring insulin sensitivity

Rapid stimulation of glucose transport by mitochondrial uncoupling depends in part on cytosolic Ca2+ and cPKC

GLUT-4myc ectopic expression in L6 myoblasts generates a GLUT-4-specific pool conferring insulin sensitivity

Heterogeneity of fractionated alveolar macrophages in starved rats

Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials

Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus

Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study

Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)

Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials

Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin : a pooled analysis of six randomized, placebo-controlled trials

Effects of ipragliflozin, a selective sodium–glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials

Effects of Ipragliflozin, a Selective Sodium–Glucose Co-Transporter 2 Inhibitor, on Blood Pressure in Japanese Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Six Randomized, Placebo-Controlled Clinical Trials

Loss of 3p26.3 is an independent prognostic factor in patients with oral squamous cell carcinoma

Suchergebnisse filtern